Can the conundrums of ACTG 175 be solved? An interview with Martin S. Hirsch, MD
- PMID: 11362965
Can the conundrums of ACTG 175 be solved? An interview with Martin S. Hirsch, MD
Abstract
AIDS: An interview with Martin S. Hirsch, planner of ACTG 175, is presented. Dr. Hirsch provides his thoughts on whether ddI monotherapy is as good as two-drug therapy; why the increase in CD4 cell counts with AZT monotherapy in treatment-naive people was less than what has been seen in other trials; whether big clinical end-point trails, like ACTG 175, can continue to be done; and whether the dropouts were consistent across arms in this trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials